Disease · MONDO_0010679
Comparisons in its trials48
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 48
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ataluren vs Placebo: DB Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 157 of 184 | 149 of 176 | 360 | NCT03179631 | Trial comparisons |
| Ataluren/Ataluren vs Placebo/Ataluren: Overall Treatment Period: Number of Participants With TEAEs | 170 of 184 | 110 of 172 | 356 | NCT03179631 | Trial comparisons |
| Ataluren vs Placebo: serious adverse events | 4 of 115 | 4 of 115 | 230 | NCT01826487 | Trial comparisons |
| GSK2402968 6mg/kg/Week vs Placebo: Number of Participants With Abnormal-clinically Significant Electrocardiogram (ECG) Findings at Any Visit Post-Baseline | 5 of 125 | 0 of 61 | 186 | NCT01254019 | Trial comparisons |
| GSK2402968 6mg/kg/Week vs Placebo: deaths from any cause | 0 of 125 | 0 of 61 | 186 | NCT01254019 | Trial comparisons |
| GSK2402968 6mg/kg/Week vs Placebo: serious adverse events | 13 of 125 | 5 of 61 | 186 | NCT01254019 | Trial comparisons |
| Givinostat vs Placebo: deaths from any cause | 0 of 118 | 0 of 61 | 179 | NCT02851797 | Trial comparisons |
| Givinostat vs Placebo: serious adverse events | 8 of 118 | 2 of 61 | 179 | NCT02851797 | Trial comparisons |
| Golodirsen vs Casimersen: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs) | 12 of 74 | 22 of 97 | 171 | NCT03532542 | Trial comparisons |
| Golodirsen vs Casimersen: deaths from any cause | 1 of 74 | 0 of 97 | 171 | NCT03532542 | Trial comparisons |
| Golodirsen vs Casimersen: serious adverse events | 12 of 74 | 22 of 97 | 171 | NCT03532542 | Trial comparisons |
| Dose 1 vs Placebo: deaths from any cause | 0 of 88 | 0 of 43 | 131 | NCT03703882 | Trial comparisons |
| Dose 1 vs Placebo: serious adverse events | 1 of 88 | 1 of 43 | 131 | NCT03703882 | Trial comparisons |
| Domagrozumab vs Placebo: Number of Participants With Vital Signs Findings Reported as SAEs by Week 49 | 0 of 80 | 0 of 40 | 120 | NCT02310763 | Trial comparisons |
| Eteplirsen 30 mg/kg vs Untreated Control Group (Non-exon 51 Amenable Participants): deaths from any cause | 0 of 79 | 0 of 30 | 109 | NCT02255552 | Trial comparisons |
| Eteplirsen 30 mg/kg vs Untreated Control Group (Non-exon 51 Amenable Participants): serious adverse events | 11 of 79 | 2 of 30 | 109 | NCT02255552 | Trial comparisons |
| Eteplirsen 30 mg/kg vs Untreated Control Group (Non-exon 51 Amenable Participants): Number of Participants Who Lost Ambulation (LOA) by Week 96 | 12 of 67 | 1 of 20 | 87 | NCT02255552 | Trial comparisons |
| Viltolarsen vs Placebo: deaths from any cause | 0 of 38 | 0 of 39 | 77 | NCT04060199 | Trial comparisons |
| Viltolarsen vs Placebo: serious adverse events | 2 of 38 | 3 of 39 | 77 | NCT04060199 | Trial comparisons |
Eteplirsen 30 mg/kg vs Untreated Control Group (Non-exon 51 Amenable Participants): Number of Participants Having Ability to Rise Independently From the Floor Determined Based on North Star Ambulatory Assessment (NSAA) at Week 96 | 33 of 61 | 3 of 9 | 70 | NCT02255552 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010679/comparisons